磷酸西格列汀联合甘精胰岛素治疗2型糖尿病的临床疗效及安全性(1)
[摘要] 目的 探讨磷酸西格列汀联合甘精胰岛素治疗2型糖尿病的临床疗效与安全性。 方法 选取该院于2014年3月—2015年3月间收治2型糖尿病患者86例，随机分成对照组与观察组，每组43例。对照组患者给予甘精胰岛素皮下注射治疗，观察组患者在对照组的基础上加用磷酸西格列汀口服治疗，两组患者疗程均为3个月。观察对比两组患者治疗前后空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbAlc)及体重指数(BMI)变化情况，并记录两组患者治疗期间不良反应的发生情况。 结果 治疗1个疗程后两组患者的FPG、2 hPG、HbAlc及BMI水平均显著优于治疗前，且观察组患者2 hPG、HbAlc及BMI的改善程度显著优于对照组，差异有统计学意义(P<0.05)；同时治疗组患者不良反应发生率为7.0%，显著低于对照组25.6%，差异有统计学意义(P<0.05)。结论 相比于单纯甘精胰岛素治疗口服降糖药物血糖控制不佳的2型糖尿病患者来说，磷酸西格列汀联合甘精胰岛素治疗的效果更好，且安全性更高，值得临床推广应用。
[关键词] 磷酸西格列汀；甘精胰岛素；2型糖尿病；疗效
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2017)09(b)-0013-03
Clinical Curative Effect and Safety of Sitagliptin Phosphate and Insulin Glargine in Treatment of Type 2 Diabetes
CHEN Xiang-feng
Shuangji Hospital， Jilin， Jilin Province， 132102 China
[Abstract] Objective To study the clinical curative effect and safety of sitagliptin phosphate and Insulin glargine in treatment of type 2 diabetes. Methods 86 cases of type 2 diabetes patients admitted and treated in our hospital from March 2014 to March 2015 were selected and randomly divided into two groups with 43 cases in each， the control group adopted the subcutaneous injection of insulin glargine， while the observation group adopted the oral administration of sitagliptin phosphate on the basis of the control group， and the treatment course of the two groups was three months， and the changes of FPG， 2 hPG， HbAlc and BMI were compared before and after treatment. Results After 1 treatment course， the FPG， 2 hPG， HbAlc， BMI levels of the two groups were obviously better than those before treatment， and the improvement degrees of 2 hPG，HbAlc， BMI in the observation group were obviously better than those in the control group， and the differences were statistically significant(P<0.05)， at the same time， the incidence rate of adverse reactions in the treatment group was obviously lower than that in the control group， (7.0% vs 25.6%)， and the differences were statistically significant(P<0.05). Conclusion The treatment effect of sitagliptin phosphate and insulin glargine in treatment of type 2 diabetes is better than that of simple insulin glargine， and the safety is high， and it is worth clinical promotion and application.
[Key words] Sitagliptin phosphate； Insulin glargine； Type 2 diabetes； Curative effect
由于受到多種因素的影响，糖尿病发病率正逐年上升，目前我国大约有9 000万糖尿病患者，患病人数已跃居世界第一[1]。糖尿病可分为Ⅰ型糖尿病和2型糖尿病，其中2型糖尿病患者占糖尿病患者总数的95%左右，主要表现出持续性胰岛素抵抗和进行性胰岛β细胞功能障碍或丧失[2]。目前，临床上尚无根治2型糖尿病的有效治疗手段，主要采用控制血糖、缓解并发症及以提高生存质量为宗旨对患者进行对症治疗。但是随着患者疾病的不断进展，单纯的口服降糖药物来进行治疗已经不能到达理想的效果[3]，因此目前临床上多采用口服降糖药物联合胰岛素注射来进行2型糖尿病的治疗。该研究选取2014年3月—2015年3月收治的86例患者为研究对象，通过观察磷酸西格列汀联合甘精胰岛素治疗血糖控制不佳的2型糖尿病的临床疗效与安全性，旨在寻找一种更为有效的治疗手段，现报道如下。, 百拇医药(陈香凤)
[关键词] 磷酸西格列汀；甘精胰岛素；2型糖尿病；疗效
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2017)09(b)-0013-03
Clinical Curative Effect and Safety of Sitagliptin Phosphate and Insulin Glargine in Treatment of Type 2 Diabetes
CHEN Xiang-feng
Shuangji Hospital， Jilin， Jilin Province， 132102 China
[Abstract] Objective To study the clinical curative effect and safety of sitagliptin phosphate and Insulin glargine in treatment of type 2 diabetes. Methods 86 cases of type 2 diabetes patients admitted and treated in our hospital from March 2014 to March 2015 were selected and randomly divided into two groups with 43 cases in each， the control group adopted the subcutaneous injection of insulin glargine， while the observation group adopted the oral administration of sitagliptin phosphate on the basis of the control group， and the treatment course of the two groups was three months， and the changes of FPG， 2 hPG， HbAlc and BMI were compared before and after treatment. Results After 1 treatment course， the FPG， 2 hPG， HbAlc， BMI levels of the two groups were obviously better than those before treatment， and the improvement degrees of 2 hPG，HbAlc， BMI in the observation group were obviously better than those in the control group， and the differences were statistically significant(P<0.05)， at the same time， the incidence rate of adverse reactions in the treatment group was obviously lower than that in the control group， (7.0% vs 25.6%)， and the differences were statistically significant(P<0.05). Conclusion The treatment effect of sitagliptin phosphate and insulin glargine in treatment of type 2 diabetes is better than that of simple insulin glargine， and the safety is high， and it is worth clinical promotion and application.
[Key words] Sitagliptin phosphate； Insulin glargine； Type 2 diabetes； Curative effect
由于受到多種因素的影响，糖尿病发病率正逐年上升，目前我国大约有9 000万糖尿病患者，患病人数已跃居世界第一[1]。糖尿病可分为Ⅰ型糖尿病和2型糖尿病，其中2型糖尿病患者占糖尿病患者总数的95%左右，主要表现出持续性胰岛素抵抗和进行性胰岛β细胞功能障碍或丧失[2]。目前，临床上尚无根治2型糖尿病的有效治疗手段，主要采用控制血糖、缓解并发症及以提高生存质量为宗旨对患者进行对症治疗。但是随着患者疾病的不断进展，单纯的口服降糖药物来进行治疗已经不能到达理想的效果[3]，因此目前临床上多采用口服降糖药物联合胰岛素注射来进行2型糖尿病的治疗。该研究选取2014年3月—2015年3月收治的86例患者为研究对象，通过观察磷酸西格列汀联合甘精胰岛素治疗血糖控制不佳的2型糖尿病的临床疗效与安全性，旨在寻找一种更为有效的治疗手段，现报道如下。, 百拇医药(陈香凤)